Genetic Analysis of Thyrotoxic Periodic Paralysis

This study has been completed.

Sponsor:

Information provided by:

Ramathibodi Hospital

ClinicalTrials.gov Identifier:

NCT00443833

First received: March 5, 2007

Last updated: NA

Last verified: March 2007

History: No changes posted

Tracking Information

First Received Date ^ICMJE

March 5, 2007

Last Updated Date

March 5, 2007

Start Date ^ICMJE

January 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Genetic Analysis of Thyrotoxic Periodic Paralysis

Official Title ^ICMJE

Genetic Analysis of Thai Patients With Thyrotoxic Periodic Paralysis

Brief Summary

Thyrotoxic periodic paralysis (TPP) is characterized by episodes of reversible hypokalemia and weakness in thyrotoxic patients. It is commonly found in males of Asian descent and is also seen in individuals having Native American or Hispanic ancestry. Therefore genetic etiology has been hypothesized. This study, we aim to find the susceptibility genes that associate with TPP. Both candidate genes approach and genome wide association study have been conducted.

Detailed Description

This study is a genetic association study. It included 50 cases of TPP patients and 80 cases of male, hyperthyroid patients who didn't have hypokalemia as a well characterized controls. After informed consent were obtained, genomic DNA from leukocyte were extracted. Pooled DNA were constructed and whole genome scan using 10K GeneChip microarray were genotyped on pooled genomic DNA.

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Retrospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

Not Provided

Condition ^ICMJE

Thyrotoxic Periodic Paralysis

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

December 2005

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

TPP

Hyperthyroid patients from any causes
Evidence of hypokalemia (k<3.5 mg/dl)from intracellular shift (Urine K<15 mg/dl, TTKG<2)
Episodic paralysis

Exclusion Criteria:

Hypokalemia from GI or renal loss

Gender

Male

Ages

15 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT00443833

Other Study ID Numbers ^ICMJE

11-46-21

Has Data Monitoring Committee

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Ramathibodi Hospital

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Wallaya Jongjaroenprasert, MD

Endocrinology Unit, Ramathibodi Hospital, Mahidol University

Information Provided By

Ramathibodi Hospital

Verification Date

March 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top